The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
November 16th 2024
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Treatment Intensification Required, Sooner if Possible, for Many Type 2 Diabetics
A new analysis of patient records published in Diabetes Care supports rapid treatment intensification when metformin monotherapy fails in patients with type 2 diabetes mellitus (T2DM), but finds that intensification is often delayed in practice.
Howard Schatz: Moving from the Operating Room to the Dark Room
It was supposed to be just a one year sabbatical for Howard Schatz to take a break from his work as a retina specialist and enjoy what had become a growing hobby of photography. More than two decades later Schatz said he misses some parts of practice but is greatly enjoying what has become a second career.
Does Telemedicine Work for Diabetic Retinopathy Screening?
August 12th 2016In a poster presentation at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California, researchers looked at how patients responded to telemedicine in ophthalmology.
Referral Rates Are Hurting People at Risk for Vision-Threatening Diabetic Retinopathy
August 11th 2016Despite established criteria for patients at risk for vision-threatening diabetic retinopathy from the United Kingdom Prospective Diabetes Study (UKPDS), referral rates don’t reflect the number of people who should visit optometrists, ophthalmologists, and retina specialists.
Sanofi-Aventis's Adlyxin Approved by FDA for Diabetes Treatment
Following extensive clinical trials, the FDA today announced its approval of Adlyxin (lixisenatide), a once-daily injection for glycemic control. Adlyxin is a hormone that works to normalize blood sugar levels, and could be a treatment option for the well-over 25 million Americans living with Type 2 diabetes.
Flu Shots Curb Breathing, Heart Problems in Diabetics
While the influenza vaccine has endured its fair share of controversy, new research shed light on one of the flu shot’s added benefits: diabetes patients who get the vaccine may not suffer as many cardiovascular or respiratory problems.
The Effects of Dietary Fat and Carbohydrate on Metabolic Health
A new meta-analysis of 102 randomized controlled diet trials found that consumption of polyunsaturated fat instead of carbohydrate or saturated fat reduces blood sugar levels and insulin resistance while also increasing the body’s ability to make insulin.
David Nash: Helping Doctors Transition to Population Health
For many veteran doctors there may be a leaning toward staying the course that has guided them through their careers. As times change there have been signs that doctors must also adapt to the changing medical landscape.
David Nash from Thomas Jefferson University: An Introduction to Population Health at the ACC
At the American College of Cardiology's annual meeting in Chicago the opening discussion in front of thousands of the top doctors across the country focused on a developing specialty aimed at improving patient health in non-traditional ways.